Why Treat UP with Suppositories?

High concentration of 5-ASA at the site of inflammation is key to treatment success.1,

  • Suppositories provide highest local concentration 5-ASA and the lowest systemic exposure2

Suppositories are appropriate for ulcerative proctitis.

  • More than 90% of the liquid in the 5-ASA enemas tends to bypass the rectum3
  • Patients prefer suppositories to enemas4
  • Suppositories are much more practical and easier to hold than enemas5



Information on this website is not intended to replace the advice of your physician(s). Please consider what you learn here a starting point for a conversation with your physician. All care of ulcerative proctitis and related conditions must be guided by the appropriate healthcare professional. CANASA® is a prescription drug.

References
1.Travis SPL. Which 5-ASA? Gut. 2002;51:548–549. 2.Williams CN. Efficacy and tolerance of 5-aminosalicylic acid suppositories in the treatment of ulcerative proctitis: A review of two double- blind, placebo controlled trials. Can J Gastroenterol 1990; 4:472-475. 3.van Bodegraven AA, Boer RO, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther. 1996;10:327-332. 4.Farup PG, Hovde O, Halvorsen FA, et al. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol. 1995;30:164-170. 5.Campieri M, Gionchetti P, Belluzzi A, et al. 5-aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin GastroenteroI. 1988;10:406-409.

 

CANASA® is available by prescription only.

CANASA® 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis.

CANASA® is contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated fatty acid esters (Hard Fat, NF)], or to salicylates (including Aspirin).

As with other mesalamine containing products, less common but possibly serious side effects such as acute intolerance syndrome, pericarditis and pancolitis may occur.

Patients on CANASA® 1000 mg, especially those on concurrent oral products which contain or release mesalamine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.

Caution should be exercised when CANASA® suppositories are initially used in patients known to be allergic to sulfasalazine.

CANASA® was generally well tolerated in clinical studies. The most common side effects of CANASA® are dizziness (3%), rectal pain (1.8%), fever (1.2%), rash (1.2%), acne (1.2%), and colitis (1.2%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.